Relighting Photosensitizers by Synergistic Integration of Albumin and Perfluorocarbon for Enhanced Photodynamic Therapy.
Hao Ren,Jiaqi Liu,Fenhong Su,Sizhan Ge,Ahu Yuan,Weimin Dai,Jinhui Wu,Yiqiao Hu
DOI: https://doi.org/10.1021/acsami.6b14885
IF: 9.5
2017-01-01
ACS Applied Materials & Interfaces
Abstract:Photodynamic therapy (PDT) is hampered by poor water solubility and skin phototoxicity of photosensitizers (PSs). Incorporation of PSs into nanocarrier (Nano-PDT) has been designed to overcome these problems. However, self quenching of PSs highly condensed in Nano-PDT significantly reduced singlet oxygen (O-1(2)) generation, resulting in unsatisfactory PDT efficacy. Here, we developed a novel tripleffect Nano-PDT, which has a special core shell nanostructure by synergistic integration of perfluorotributyl- amine (PFTBA) and human serum albumin (HSA) to improve PDT. It has three mechanisms to relight quenched PSs, thereby generating more O-1(2). First, PSs uniformly dispersed in the shell, preventing self-quenching caused by pi-pi stacking. Second, HSA as nanocarrier extends the triplet-state lifetimes of PSs, increasing the amount of O-1(2). Third, PFTBA as core dissolves and protects' O-1(2) to extend the duration time of action of O-1(2). Compared with PS-encapsulated Nano-PDT, the self-quenching of PSs in tripleffect Nano-PDT can be effectively overcome. The fluorescence and O-1(2) generation of PS are increased by approximately 100-fold and 15-fold, respectively. After intravenous injection into tumor-bearing mice, the tumor growth is significantly inhibited, while the PS-encapsulated Nano-PDT has almost no effect. The novel tripleffect Nano-PDT may guide improvement of existing clinical PDT and future PDT design.